Published in Sci Transl Med on June 30, 2010
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature (2012) 20.47
Heterogeneity in breast cancer. J Clin Invest (2011) 2.86
Genome-wide copy number analysis of single cells. Nat Protoc (2012) 2.47
Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Res Treat (2011) 2.23
Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc Natl Acad Sci U S A (2011) 2.18
ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium. EMBO Mol Med (2011) 2.07
Insight into the heterogeneity of breast cancer through next-generation sequencing. J Clin Invest (2011) 1.99
Copynumber: Efficient algorithms for single- and multi-track copy number segmentation. BMC Genomics (2012) 1.74
Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation. PLoS One (2012) 1.72
Systems biology and genomics of breast cancer. Cold Spring Harb Perspect Biol (2011) 1.59
A new genome-driven integrated classification of breast cancer and its implications. EMBO J (2013) 1.47
Functional genomic analysis of chromosomal aberrations in a compendium of 8000 cancer genomes. Genome Res (2012) 1.39
FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo. Clin Cancer Res (2011) 1.29
The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun (2016) 1.15
What are we learning from the cancer genome? Nat Rev Clin Oncol (2012) 1.13
COLT-Cancer: functional genetic screening resource for essential genes in human cancer cell lines. Nucleic Acids Res (2011) 1.08
The molecular diversity of Luminal A breast tumors. Breast Cancer Res Treat (2013) 1.07
DDX5 regulates DNA replication and is required for cell proliferation in a subset of breast cancer cells. Cancer Discov (2012) 1.02
Target inference from collections of genomic intervals. Proc Natl Acad Sci U S A (2013) 1.02
Immunophenotypic and genomic characterization of papillary carcinomas of the breast. J Pathol (2011) 0.95
Systems consequences of amplicon formation in human breast cancer. Genome Res (2014) 0.95
Optimizing sparse sequencing of single cells for highly multiplex copy number profiling. Genome Res (2015) 0.95
A new gene expression signature, the ClinicoMolecular Triad Classification, may improve prediction and prognostication of breast cancer at the time of diagnosis. Breast Cancer Res (2011) 0.93
Long non-coding RNAs differentially expressed between normal versus primary breast tumor tissues disclose converse changes to breast cancer-related protein-coding genes. PLoS One (2014) 0.92
Divide and conquer: the genetic basis of molecular subclassification of breast cancer. EMBO Mol Med (2011) 0.91
Loss of 18q22.3 involving the carboxypeptidase of glutamate-like gene is associated with poor prognosis in resected pancreatic cancer. Clin Cancer Res (2011) 0.89
Assessment of palindromes as platforms for DNA amplification in breast cancer. Genome Res (2011) 0.88
Chromosome-breakage genomic instability and chromothripsis in breast cancer. BMC Genomics (2014) 0.87
Simultaneous copy number gains of NUPR1 and ERBB2 predicting poor prognosis in early-stage breast cancer. BMC Cancer (2012) 0.87
Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer. Breast Cancer Res (2011) 0.87
Enhancing sensitivity and specificity in rare cell capture microdevices with dielectrophoresis. Biomicrofluidics (2015) 0.86
Characterization of microfluidic shear-dependent epithelial cell adhesion molecule immunocapture and enrichment of pancreatic cancer cells from blood cells with dielectrophoresis. Biomicrofluidics (2014) 0.86
Somatic copy number alterations detected by ultra-deep targeted sequencing predict prognosis in oral cavity squamous cell carcinoma. Oncotarget (2015) 0.86
Identifying in-trans process associated genes in breast cancer by integrated analysis of copy number and expression data. PLoS One (2013) 0.86
Micro-scale genomic DNA copy number aberrations as another means of mutagenesis in breast cancer. PLoS One (2012) 0.85
Major chromosomal breakpoint intervals in breast cancer co-localize with differentially methylated regions. Front Oncol (2012) 0.84
Genome aberrations in canine mammary carcinomas and their detection in cell-free plasma DNA. PLoS One (2013) 0.84
Structural analysis of the genome of breast cancer cell line ZR-75-30 identifies twelve expressed fusion genes. BMC Genomics (2012) 0.83
An array CGH based genomic instability index (G2I) is predictive of clinical outcome in breast cancer and reveals a subset of tumors without lymph node involvement but with poor prognosis. BMC Med Genomics (2012) 0.83
Identification of Novel Breast Cancer Subtype-Specific Biomarkers by Integrating Genomics Analysis of DNA Copy Number Aberrations and miRNA-mRNA Dual Expression Profiling. Biomed Res Int (2015) 0.82
The breast cancer genome--a key for better oncology. BMC Cancer (2011) 0.82
High levels of genomic aberrations in serous ovarian cancers are associated with better survival. PLoS One (2013) 0.82
'Omic approaches to preventing or managing metastatic breast cancer. Breast Cancer Res (2011) 0.81
The potential for chemical mixtures from the environment to enable the cancer hallmark of sustained proliferative signalling. Carcinogenesis (2015) 0.81
Genomic profiling of breast cancers. Curr Opin Obstet Gynecol (2015) 0.80
Canine Mammary Tumours Are Affected by Frequent Copy Number Aberrations, including Amplification of MYC and Loss of PTEN. PLoS One (2015) 0.79
A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer. Mol Oncol (2014) 0.78
Nuclear CSPP1 expression defined subtypes of basal-like breast cancer. Br J Cancer (2014) 0.78
Genomic instability: a stronger prognostic marker than proliferation for early stage luminal breast carcinomas. PLoS One (2013) 0.78
Characterization of genomic alterations in radiation-associated breast cancer among childhood cancer survivors, using comparative genomic hybridization (CGH) arrays. PLoS One (2015) 0.78
Differential expression of neurogenes among breast cancer subtypes identifies high risk patients. Oncotarget (2016) 0.78
Quantitative multigene FISH on breast carcinomas identifies der(1;16)(q10;p10) as an early event in luminal A tumors. Genes Chromosomes Cancer (2014) 0.77
Trastuzumab and docetaxel in a preclinical organotypic breast cancer model using tissue slices from mammary fat pad: Translational relevance. Oncol Rep (2015) 0.76
An integrated genomics analysis of epigenetic subtypes in human breast tumors links DNA methylation patterns to chromatin states in normal mammary cells. Breast Cancer Res (2016) 0.76
The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells - A data description. Genom Data (2014) 0.76
Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response. Breast Cancer (Dove Med Press) (2017) 0.75
Emerging Role of Genomic Rearrangements in Breast Cancer: Applying Knowledge from Other Cancers. Biomark Cancer (2016) 0.75
‘The charmingest place’: non-coding RNA, lineage tracing, tumor heterogeneity, metastasis and metabolism--new methods in mammary gland development and cancer: the fifth ENBDC Workshop. Breast Cancer Res (2013) 0.75
Identification of genomic functional hotspots with copy number alteration in liver cancer. EURASIP J Bioinform Syst Biol (2013) 0.75
Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome. Breast Cancer Res (2017) 0.75
Genomics: A broad brush. Nat Rev Cancer (2010) 0.75
A systematic comparison of copy number alterations in four types of female cancer. BMC Cancer (2016) 0.75
Cancer classification in the genomic era: five contemporary problems. Hum Genomics (2015) 0.75
A new tumor biomarker, serum protein peak at 3,144 m/z, in patients with node-positive breast cancer. Clin Transl Oncol (2014) 0.75
Data-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexity. Oncotarget (2017) 0.75
Bioconductor: open software development for computational biology and bioinformatics. Genome Biol (2004) 143.19
Molecular portraits of human breast tumours. Nature (2000) 94.14
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet (2008) 43.63
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 42.90
Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA (2006) 24.01
The Stability of Broken Ends of Chromosomes in Zea Mays. Genetics (1941) 16.95
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell (2006) 16.05
Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature (2009) 13.45
Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med (2009) 10.88
Representational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variation. Genome Res (2003) 7.86
Allele-specific copy number analysis of tumors. Proc Natl Acad Sci U S A (2010) 7.70
Epidemiology of basal-like breast cancer. Breast Cancer Res Treat (2007) 7.08
Inferring tumor progression from genomic heterogeneity. Genome Res (2009) 6.09
Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst (2008) 5.74
Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer (2006) 5.39
The Behavior in Successive Nuclear Divisions of a Chromosome Broken at Meiosis. Proc Natl Acad Sci U S A (1939) 5.06
REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer (2005) 4.85
High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol (2007) 4.70
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One (2009) 4.62
An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol (2007) 4.33
Novel patterns of genome rearrangement and their association with survival in breast cancer. Genome Res (2006) 4.25
Comparative genomic hybridization using oligonucleotide microarrays and total genomic DNA. Proc Natl Acad Sci U S A (2004) 3.82
Resolving the resolution of array CGH. Genomics (2007) 3.66
Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer (2006) 3.34
Breast cancer: origins and evolution. J Clin Invest (2007) 3.31
Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab (2004) 3.10
TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res (2007) 3.01
Integrated profiling of basal and luminal breast cancers. Cancer Res (2007) 2.86
CGH-Explorer: a program for analysis of array-CGH data. Bioinformatics (2004) 2.65
Genomic imbalances in 5918 malignant epithelial tumors: an explorative meta-analysis of chromosomal CGH data. BMC Cancer (2007) 2.27
Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. Cancer Res (1997) 2.22
Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol (2003) 2.13
Comparison of the Agilent, ROMA/NimbleGen and Illumina platforms for classification of copy number alterations in human breast tumors. BMC Genomics (2008) 2.11
Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer. Mol Oncol (2007) 2.06
Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res (1997) 2.03
Human and mouse oligonucleotide-based array CGH. Nucleic Acids Res (2005) 2.03
Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest (2008) 1.80
Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers. Oncogene (2006) 1.74
Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis. Mod Pathol (2006) 1.62
Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes. Breast Cancer Res (2009) 1.59
Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res (2007) 1.58
Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. BMC Cancer (2006) 1.58
The pitfalls of platform comparison: DNA copy number array technologies assessed. BMC Genomics (2009) 1.55
Challenges in projecting clustering results across gene expression-profiling datasets. J Natl Cancer Inst (2007) 1.52
Characterization of chromosomal anomalies in human breast cancer. A comparison of 30 paradiploid cases with few chromosome changes. Cancer Genet Cytogenet (1990) 1.45
Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family. Am J Surg Pathol (2008) 1.41
Origins of breast cancer subtypes and therapeutic implications. Nat Clin Pract Oncol (2007) 1.36
Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least two different lines of genetic evolution. J Pathol (2001) 1.26
Chromosome 5 imbalance mapping in breast tumors from BRCA1 and BRCA2 mutation carriers and sporadic breast tumors. Int J Cancer (2006) 1.20
Portraits of breast cancer progression. BMC Bioinformatics (2007) 1.17
Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer. BMC Med Genomics (2009) 1.09
PMC42, a breast progenitor cancer cell line, has normal-like mRNA and microRNA transcriptomes. Breast Cancer Res (2008) 1.04
Loss of 16q in high grade breast cancer is associated with estrogen receptor status: Evidence for progression in tumors with a luminal phenotype? Genes Chromosomes Cancer (2009) 1.02
Deciphering a subgroup of breast carcinomas with putative progression of grade during carcinogenesis revealed by comparative genomic hybridisation (CGH) and immunohistochemistry. Br J Cancer (2004) 1.00
Cytogenetic clues to breast carcinogenesis. Genes Chromosomes Cancer (2002) 1.00
Genomic differences between pure ductal carcinoma in situ of the breast and that associated with invasive disease: a calibrated aCGH study. Clin Cancer Res (2008) 0.99
Karyotypic evolution in breast carcinomas with i(1)(q10) and der(1;16)(q10;p10) as the primary chromosome abnormality. Cancer Genet Cytogenet (1999) 0.98
Co-amplification of 8p12 and 11q13 in breast cancers is not the result of a single genomic event. Genes Chromosomes Cancer (2007) 0.96
Chromosomal rearrangements and oncogene amplification precede aneuploidization in the genetic evolution of breast cancer. Cancer Res (2001) 0.95
Ploidy level determinations in high-grade and low-grade malignant variants of prostatic carcinoma. Cancer Res (1990) 0.94
Near tetraploid prostate carcinoma. Methodologic and prognostic aspects. Cancer (1996) 0.90
Simultaneous chromosome 1q gain and 16q loss is associated with steroid receptor presence and low proliferation in breast carcinoma. Mod Pathol (2004) 0.86
Characterization of a new cytogenetic subtype of ductal breast carcinomas. Oncogene (2004) 0.80
The contribution of de novo coding mutations to autism spectrum disorder. Nature (2014) 5.94
PTEN action in leukaemia dictated by the tissue microenvironment. Nature (2014) 1.06
SMASH, a fragmentation and sequencing method for genomic copy number analysis. Genome Res (2016) 0.75